ChroMedX Announces Exercise of Warrants

ChroMedX Corp. (CSE:CHX) (OTC: CHXIF) (FSE: EIY2) (the “Company”), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that since November 2017 investors have exercised warrants to acquire 1,031,000 new common shares of the Company as of December 12, 2017.
The total consideration received was CAD$226,200. The Warrant Shares will rank pari passu in all respects with the existing common shares of the Company.
Recent News
The Company most recently announced the appointment of Dr. Richard Janeczko to its board of Directors.
Dr. Janeczko is a veteran of the medical diagnostics industry with more than 25 years’ experience in development and commercial transaction of novel technology and device companies. He has worked in multiple clinical areas including critical care medicine, oncology and infectious disease driving value-based strategies for companies bringing advanced diagnostics into medical practice. Richard is also the CEO of DxEconomix Inc., a Glendale, California headquartered diagnostic marketing firm.
All ChroMedX News can be found on the Company’s website at www.chromedx.com
Website
Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company’s website at www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis technology which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing technologies require users to purchase a second device to carry out the CO-oximetry. The Company’s technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.
The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion $US in 2015 and is projected to reach over 1.8 Billion by 2020.
Website: www.chromedx.com
Contact:
Gerard Edwards
Executive Chairman
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@chromedx.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
Click here to connect with ChroMedX Corp. (CSE:CHX) (OTC: CHXIF) to receive an Investor Presentation

Source: www.newsfilecorp.com